Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Guy Neff, Cynthia D. Guy, Mustafa R. Bashir, Angelo H. Paredes, Juan P. Frias, Ziad Younes, James F. Trotter, Nadege T. Gunn, Sam E. Moussa, Anita Kohli, Kristin Nelson, Mildred Gottwald, William C.G. Chang, Andrew Z. Yan, Alex M. DePaoli, Lei Ling, Hsiao D. Lieu

Open source

DOI: 10.1053/j.gastro.2020.08.004
Published: 2021-01
Container: Gastroenterology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1053/j.gastro.2020.08.004,
  title = {Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis},
  author = {Stephen A. Harrison and Guy Neff and Cynthia D. Guy and Mustafa R. Bashir and Angelo H. Paredes and Juan P. Frias and Ziad Younes and James F. Trotter and Nadege T. Gunn and Sam E. Moussa and Anita Kohli and Kristin Nelson and Mildred Gottwald and William C.G. Chang and Andrew Z. Yan and Alex M. DePaoli and Lei Ling and Hsiao D. Lieu},
  year = {2021},
  journal = {Gastroenterology},
  doi = {10.1053/j.gastro.2020.08.004},
  url = {https://doi.org/10.1053/j.gastro.2020.08.004}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
AU  - Stephen A. Harrison
AU  - Guy Neff
AU  - Cynthia D. Guy
AU  - Mustafa R. Bashir
AU  - Angelo H. Paredes
AU  - Juan P. Frias
AU  - Ziad Younes
AU  - James F. Trotter
AU  - Nadege T. Gunn
AU  - Sam E. Moussa
AU  - Anita Kohli
AU  - Kristin Nelson
AU  - Mildred Gottwald
AU  - William C.G. Chang
AU  - Andrew Z. Yan
AU  - Alex M. DePaoli
AU  - Lei Ling
AU  - Hsiao D. Lieu
PY  - 2021
JO  - Gastroenterology
DO  - 10.1053/j.gastro.2020.08.004
UR  - https://doi.org/10.1053/j.gastro.2020.08.004
ER  -

APA

Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., Kohli, A., Nelson, K., Gottwald, M., Chang, W. C., Yan, A. Z., DePaoli, A. M., Ling, L., & Lieu, H. D. (2021). Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology. https://doi.org/10.1053/j.gastro.2020.08.004

Source records

crossref · retrieved 2026-09-26T06:54:20.891Z